Intro

This chapter explores groundbreaking strategies in decentralized CAR-T therapy manufacturing, featuring a Swiss company's partnership with renowned academic institutions. It emphasizes the significance of early collaboration and reimagining process development for scalable solutions by the end of phase one clinical trials.